Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS PR Newswire BOSTON and SAN DIEGO and...
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...
CALGARY, Alberta and SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
- Increased PD-L1 expression correlates with clinical response when pelareorep is combined with a proteasome inhibitor - - Data continue to recommend pelareorep as a standardized backbone for...
CALGARY, Alberta and SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
CALGARY, Alberta and SAN DIEGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
CALGARY, Alberta and SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference...
- Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1 | 8.26446280992 | 1.21 | 1.35 | 1.02 | 187410 | 1.14989048 | CS |
| 4 | -0.08 | -5.75539568345 | 1.39 | 1.4 | 1.02 | 107787 | 1.22133874 | CS |
| 12 | 0.1 | 8.26446280992 | 1.21 | 2.08 | 1.02 | 133136 | 1.5264046 | CS |
| 26 | -0.08 | -5.75539568345 | 1.39 | 2.08 | 1.02 | 81580 | 1.47985629 | CS |
| 52 | -0.42 | -24.2774566474 | 1.73 | 2.08 | 1.02 | 74285 | 1.48969871 | CS |
| 156 | -0.55 | -29.5698924731 | 1.86 | 4.49 | 1.02 | 80369 | 2.22386134 | CS |
| 260 | -1.04 | -44.2553191489 | 2.35 | 7.84 | 1.02 | 133060 | 3.10610746 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
